Revenue Breakdown
Composition ()
No data
Revenue Streams
Sanara Medtech Inc (SMTI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Soft tissue repair products, accounting for 89.0% of total sales, equivalent to $23.42M. Another important revenue stream is Bone fusion products. Understanding this composition is critical for investors evaluating how SMTI navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Sanara Medtech Inc maintains a gross margin of 90.56%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 11.74%, while the net margin is 3.17%. These profitability ratios, combined with a Return on Equity (ROE) of -26.46%, provide a clear picture of how effectively SMTI converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, SMTI competes directly with industry leaders such as SKIN and CRDF. With a market capitalization of $186.04M, it holds a significant position in the sector. When comparing efficiency, SMTI's gross margin of 90.56% stands against SKIN's 64.59% and CRDF's 100.00%. Such benchmarking helps identify whether Sanara Medtech Inc is trading at a premium or discount relative to its financial performance.
